Novavax Inc. [NASDAQ: NVAX] jumped around 0.5 points on Wednesday, while shares priced at $6.66 at the close of the session, up 8.12%. The company report on March 6, 2023 that Novavax to Participate in TD Cowen’s 43rd Annual Health Care Conference.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen’s 43rd Annual Health Care Conference.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Novavax Inc. stock is now -35.21% down from its year-to-date (YTD) trading value. NVAX Stock saw the intraday high of $6.71 and lowest of $6.20 per share. The company’s 52-week high price is 82.30, which means current price is +18.82% above from all time high which was touched on 01/18/23.
Compared to the average trading volume of 6.67M shares, NVAX reached a trading volume of 4267547 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Novavax Inc. [NVAX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $50.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 01, 2023. While these analysts kept the previous recommendation, B. Riley Securities dropped their target price from $74 to $37. The new note on the price target was released on January 09, 2023, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another drop from $207 to $110, while H.C. Wainwright kept a Buy rating on NVAX stock.
The Average True Range (ATR) for Novavax Inc. is set at 0.54, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 0.28.
How has NVAX stock performed recently?
Novavax Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.22. With this latest performance, NVAX shares dropped by -28.08% in over the last four-week period, additionally sinking by -66.77% over the last 6 months – not to mention a drop of -91.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 43.38, with the RSI for the last a single of trading hit 53.40, and the three-weeks RSI is set at 39.63 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 8.80, while it was recorded at 6.14 for the last single week of trading, and 25.17 for the last 200 days.
Novavax Inc. [NVAX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -64.27 and a Gross Margin at +43.55. Novavax Inc.’s Net Margin is presently recorded at -41.15.
Reflecting on the efficiency of the workforce at the company, Novavax Inc. [NVAX] managed to generate an average of -$330,291 per employee. Receivables Turnover for the company is 5.95 with a Total Asset Turnover recorded at a value of 0.66.Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.
Insider trade positions for Novavax Inc. [NVAX]
There are presently around $324 million, or 47.00% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 8,844,653, which is approximately 17.993% of the company’s market cap and around 0.30% of the total institutional ownership; STATE STREET CORP, holding 6,076,518 shares of the stock with an approximate value of $37.43 million in NVAX stocks shares; and BLACKROCK INC., currently with $29.5 million in NVAX stock with ownership of nearly 10.673% of the company’s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 124 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 20,878,913 shares. Additionally, 112 investors decreased positions by around 4,455,928 shares, while 59 investors held positions by with 27,213,317 shares. The mentioned changes placed institutional holdings at 52,548,158 shares, according to the latest SEC report filing. NVAX stock had 45 new institutional investments in for a total of 8,708,520 shares, while 48 institutional investors sold positions of 1,716,597 shares during the same period.